References
- Archer DF. Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives. Contraception 2006;74:359–366.
- Edelman A, Gallo MF, Nichols MD, et al Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials. Hum Reprod 2006;21:573–578.
- Vandever MA, Kuehl TJ, Sulak PJ, et al Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens. Contraception 2008;77:162–170.
- Maia H Jr, Casoy J, Pimentel K, et al Effect of oral contraceptives on vascular endothelial growth factor, Cox-2 and aromatase expression in the endometrium of uteri affected by myomas and associated pathologies. Contraception 2008;78:479–485.
- Maia HJ, Casoy J. Non-contraceptive health benefits of oral contraceptives. Eur J Contracept Reprod Health Care 2008;13:17–24.
- Sugino N, Karube-Harada A, Taketani T, et al Withdrawal of ovarian steroids stimulates prostaglandin F2α production through nuclear factor-κB activation via oxygen radicals in human endometrial stromal cells: potential relevance to menstruation. J Reprod Dev 2004;50:215–225.
- Smith OP, Jabbour HN, Critchley HO. Cyclooxygenase enzyme expression and E series prostaglandin receptor signalling are enhanced in heavy menstruation. Hum Reprod 2007;22:1450–1456.
- Maia H, Correia T, Freitas L, et al Cyclooxygenase-2 expression in the endometrium and its relationship to bleeding in users of continuous oral contraceptives. Gynecol Endocrinol 2006;22:96–100.
- Rhoton-Vlasak A, Chegini N, Hardt N, Williams RS. Histological characteristics and altered expression of interleukins (IL) IL-13 and IL-15 in endometria of levonorgestrel users with different uterine bleeding patterns. Fertil Steril 2005;83:659–665.
- Coffee AL, Sulak PJ, Kuehl TJ. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 2007;75:444–449.
- Grow DR, Iromloo K. Oral contraceptives maintain a very thin endometrium before operative hysteroscopy. Fertil Steril 2006;85:204–207.
- Sulak PJ, Scow RD, Preece C, et al Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261–266.
- Lau TM, Witjaksono J, Affandi B, Roqers PA. Expression of progesterone receptor mRNA in the endometrium during the normal menstrual cycle and in Norplant users. Hum Reprod 1996;11:2629–2634.
- Critchley HO, Jones RL, Lea RG, et al Role of inflammatory mediators in human endometrium during progesterone withdrawal and early pregnancy. J Clin Endocrinol Metab 1999;84:240–248.
- Nathirojanakun P, Taneepanichskul S, Sappakitkumjorn N. Efficacy of a selective COX-2 inhibitor for controlling irregular uterine bleeding in DMPA users. Contraception 2006;73:584–587.
- Hayes EC, Rock JA. COX-2 inhibitors and their role in gynecology. Obstet Gynecol Surv 2002;57:768–780.
- Kastner P, Krust A, Turcotte B, et al Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO Journal 1990;9:1603–1614.
- Foidart JM, Sulak PJ, Schellschmidt I, Zimmermann D; Yasmin Extended Regimen Study Group. The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days. Contraception 2006;73:34–40.
- Sales KJ, Jabbour HN. Cyclooxygenase enzymes and prostaglandins in pathology of the endometrium. Reproduction 2003;126:559–567.